Navigation Links
KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
Date:1/31/2013

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) today announced the pricing of its previously announced initial public offering of 8,750,000 shares of common stock at a price to the public of $8.00 per share, less underwriting discounts and commissions.

KaloBios has granted the underwriters a 30-day option to purchase up to 1,312,500 additional shares of common stock at the same price to cover over-allotments, if any. KaloBios' common stock will trade on the NASDAQ Global Market under the symbol "KBIO."

Leerink Swann LLC is serving as sole book-running manager for the offering. William Blair & Company, L.L.C. is serving as the lead manager and Needham & Company LLC is serving as co-manager.

A registration statement relating to these securities has been declared effective by the SEC. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, by contacting Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About KaloBios Pharmaceuticals

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Contact:

 

Je
'/>"/>


SOURCE KaloBios Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... , RIDGEFIELD, Conn., Aug. 25 Results of ... Warfarin, Compared to Dabigatran)(1) study will be presented at the ... Aug. 30. The primary objective of RE-LY was to ... thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, ...
... August 25 20% of parents seek medical,help because ... baby,and the accompanying discomfort (crying). Reputed medical journal "Archives,of ... recently,published the results of the clinical research project that ... department of the Brussels,University Hospital. , ...
Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
(Date:4/14/2014)... centers around the world, many people live and work ... that block sunlight. And as the global population continues ... darkness will only spread. , To alleviate the ... that redirects sunlight onto narrow streets and alleyways. The ... edge at an angle, where it spreads sunlight onto ...
(Date:4/14/2014)... associate professor of chemical engineering at Virginia Tech ... efficiently analyze living cells. The long-term goal is to ... , In his lab , Lu and his ... molecular events inside cells. These devices promote high sensitivity ... of cells. , Based on their record of achievements, ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
(Date:4/11/2014)... insights into the processes that control brain cell production ... and other brain-related disorders. , Scientists have gained new ... that controls how and when nerve and brain cells ... to develop and keeps it healthy. Their findings could ... of control, which is a fundamental characteristic of many ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... Some patients with large tumors on their larynx can ... surgery to remove the voice box. A new study ... a single round of chemotherapy could identify those patients most ... have excluded these patients because their tumors are so large. ...
... DC (June 25, 2009) Evidence suggests that outcomes in ... means that research into quality improvement (QI) in clinical care ... Now a study in the journal Medical Care Research ... and practical improvements in QI effectiveness studies could make these ...
... FUNCTIONING TISSUE VIOLATES MEDICAL ETHICS, HUMAN RIGHTS OF BABY BOYS ... NEW YORK, June 25 Parents, pediatricians and health and ... and its website -- www.intactamerica.org -- ... campaign argues that painful and medically unnecessary surgery to remove ...
... in German . , Providing reliable ... and labor-intensive molecular-biological procedures. Established methods are particularly hard ... very low, for example during a phase of therapy. ... micro-pumps without movable parts, scientists from the Fraunhofer Institute ...
... June 25 The YWCA USA and many of its 300 ... for Disease Control and Prevention in marking National HIV Testing Day ... to raise public awareness about the fact that one in five ... as a consequence, can unknowingly spread the deadly virus to others. ...
... June 25 The Infectious Disease Research ... M.J. Murdock Charitable Trust. This new funding will support IDRI,s efforts ... identify new drugs to treat it. , ... the air and can be hard to avoid. A seemingly insignificant ...
Cached Medicine News:Health News:U-M study finds voice box can be preserved, even with the largest cancers 2Health News:Health care outcome boost needs better studies 2Health News:Health care outcome boost needs better studies 3Health News:Health care outcome boost needs better studies 4Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 2Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 3Health News:Intact America Launches Campaign to Change How America Thinks About Male Circumcision 4Health News:Virus filters for medical diagnosis 2Health News:YWCAs to Mark National HIV Testing Day on June 27 2Health News:IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program 2Health News:IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: